Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The prognosis of ESCC is poor with a five-year overall survival rate of 10 to 30 %.
Randomized clinical trials have demonstrated that TMT, consisted of neoadjuvant concurrent
CCRT and radical esophagectomy, improves the overall survival for patients with resectable
locally advanced disease. As a consequence, it is mandatory to develop new
pharmacotherapeutic regimen for TMT. In our previous prospective studies, we found higher
levels of serum immune-related biomarkers, VEGF-A, TGF-β1, and soluble PD-L1, before
neoadjuvant CCRT were independent associated with inferior overall survival and disease-free
survival for locally advanced ESCC treated with neoadjuvant CCRT plus radical esophagectomy.
In the present clinical trial, we plan to investigate whether incorporation of tiragolumab
(Anti-TIGIT) and atezolizumab (Anti-PD-L1) into standard TMT will be safe while improve the
pathological complete response rate. By the present research, we expect to develop a new TMT
regimen for this poor prognostic disease.